Role of Interleukin - 1 alpha (IL-1α) and Regulatory T (Treg) Cells In The Pathogenesis of Inflammatory Bowel Disease

Title: Role of Interleukin - 1 alpha (IL-1α) and Regulatory T (Treg) Cells In The Pathogenesis of Inflammatory Bowel Disease

Authors: Mohamed Nabil Rafat, Mohamed Saed ELShorbagy, Magdy Abd Kareem AL Dahshan, Abd EL Gwad Saed Mohamed, Ashraf Mohamed AL Bahrawy, Mohamed Samy EL Shahawy, Mohamed Hasan Alnagar

DOI: http://dx.doi.org/10.18535/jmscr/v4i6.22

Abstract

Background: Continuous effort has been paid to deeply understanding the pathophysiology of Inflammatory bowel diseases (IBD).It has been postulated that multiple factors such as genetic susceptibility, immunological and environmental factors are involved and generate a dysregulated response of the mucosal immune system toward intraluminal antigens. Accumulating evidence indicates that discrepancy between the number of T regulatory cells (Treg) in peripheral blood and in inflamed colonic mucosa has a central role and Interleukin (IL)-1 is a key mediator in the pathogenesis of IBD.

Objective: The aim of this study was to determine the role of Interleukin- 1 alpha (IL-1α) and T regulatory (Treg) cells in the pathogenesis of IBD.

Study Design: This study was conducted in internal medicine Department of El- Hussein university hospital, AL-Azhar University. In this study, 50 subjects were selected and divided into two groups; Group A (n=30) were patients with IBD and Group B (n=20) were healthy control group. The two groups were subjected to the following; full history taking, clinical evaluation, Abdominal ultrasonography, CBC with differential count, Liver function tests, renal function tests, C-reactive protein , ESR and serum level of both Treg cells and IL-1α . IL-1α was detected in serum by ELISA and (Treg) (FoxP3) cells by flow cytometry techniques. Colonoscopy with multiple biopsies and histopathological assessment was performed to group A only.

Results: Our results showed that the serum level of Treg cells was significantly decreased in Group A (3.16±2.26) in comparison to control group B (9.14±0.639) (P<0.001). moreover ,the serum level of Treg cells was significantly decreased in moderate to severe disease activity (1.755± 0.556) as compared with patients with mild disease activity (5.980±1.616) (P<0.001) . The present study also revealed that, the serum level of IL-1α was significantly increased in patients Group A (11.74±3.24) in comparison to control Group B (2.84±0.877) (P<0.001). Additionally, the level IL-1α was significantly higher in moderate to sever disease activity (13.750 ± 1.602) than patients with mild disease activity (7.720±1.289) (P<0.001).

Conclusion: The level of Treg cells and Interleukin- 1 alpha have an important role in the pathogenesis and propagation of the inflammatory response in IBD and had a dynamic changes in both remission and active disease stages. These results suggested that Treg cells and Interleukin- 1 alpha can be used as a diagnostic markers and a potential therapeutic targets for IBD.

Keywords: inflammatory bowel disease (IBD) . Interlukin 1 alpha (IL1 α). T regulatory cell (Treg).

References

1. Danese S and Fiocchi C (2011) : Ulcerative colitis. N Eng J Med ; 365:1713–25.

2. Langan RC, Gotsch PB, Krafczyk MA and Skillinge DD(2013) : Ulcerative colitis: diagnosis and treatment. Am Fam Physician.; 76(9): 1323-30.

3. Izcue A and Powrie F(2008) : Special regulatory T-cell review: regulatory T cells and the intestinal tract – patrolling the frontier. Immunology; 123:6–10-

4. Abreu MT (20014),The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr Gastroenterol Rep ; 4: 481-489.

5. Josefowicz, S.Z., Lu, L.F. and Rudensky, A.Y. (2012) : Regulatory T Cells: Mechanisms of Differentiation and Function. Annual Review of Immunology, 30, 531-564.

6. de Rezende, L.C., Silva, I.V., Rangel, L.B. and Guimaraes, M.C. (2010): Regulatory T Cell as a Target for Cancer Therapy. Archivum Immunologiae et Therapia Experimentalis (Warsz), 58, 179-190.

7. Kawai M, Kitade H, Mathieu C, Waer M, Pirenne J. (2005): Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation. 79(9):1073–1077..

8. Wang Y, Liu XP, Zhao ZB, Chen JH, Yu CG (2011): Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. JDig Dis;12:286-294

9. Himmel ME1, Yao Y, Orban PC, Steiner TS, Levings MK (2012): Immunology. Jun;136(2):115-22. doi: 10.1111/j.1365-2567.2012.03572.x. Regulatory T-cell therapy for inflammatory bowel disease:more questions than answers.

10. Dinarello CA(2002), The IL-1 family and inflammatory diseases. Clin Exp Rheumatol.;20:S1–S13.

11. Watanabe N and Kobayashi Y (November 1994): "Selective release of a processed form of interleukin 1 alpha". Cytokine 6 (6): 597–601..

12. SatsangiJ, Wolstencroft RA, Cason J, Ainley CC(1987): Dumonde CC, Thompson RPH. Interleukin 1 in Crohn's disease. Clin Exp Immunol; 67: 594-605.

13. Collins P and Rhodes J (2006): Ulcerative colitis: diagnosis and management.BMJ; 333: 340-343

14. Schroeder KW, Tremaine WJ, Ilstrup DM. (1987): Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study N Engl J Med 1987 Vol 317 (1625-1629)

15. Best WR, Becktel JM, Singleton JW, Kern F Jr. (March 1976): "Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study". Gastroenterology 70 (3): 439–444

16. Mary JYand Modigliani R (1989): Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. Jul;30(7):983–989.

17. Elson CO, Kagnoff MF, Fiocchi C, Befus AD, (1986): Taragan S. Intestinal immunity And inflammation: recent progress. Gastroenterology; 91:746-68

18. Satsangi J, Morecroft J, Shah NB, Nimmo E. (2003) : Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol; 17: 3-18.

19. Periklis Vounotrypidis, Georgios Kouklakis, Konstantinos Anagnostopo-ulos, Petros Zezos, Alexandros Polychronidis, Efstratios Maltezos, et al., (2013): Interleukin-1 associations in inflammatory bowel disease and the enteropathic seronegative spondylarthritis, Auto Immun HighlightsDec; 4(3): 87–94. Published online 2013 Feb 22. doi: 10.1007/s13317-013-0049-4PMCID:PMC4389024

20. Blumberg RS and Strober W( 2001): Prospects for research in inflammatory bowel disease.JAMA;285:643-647.

21. Frisullo G, Nociti V, Iorio R, Plantone D, Patanella AK, Tonali PA, et al (2010): CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients. Hum Immunol.;71:437–441.

22. Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A and Barry S. (2009): Regulatory T Cells, Th17 Effector Cells and Cytokine Microenvironment in Inflammatory Bowel Disease. Accepted for publication. Journal of Clinical Immunology.

23. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, et al ., (2005): Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology; 128:1868–78.

24. Holmén N, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjövall H, et al ., (2006): Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis; 12: 447-456

25. Suen JL, Li HT, Jong YJ, Chiang BL, Yen JH (2009) : Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopula- tions in systemic lupus erythematosus. Immunology; 127: 196-205

26. Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, et al., (1982) : Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest.;12:351 –359.

Corresponding Author

Mohamed Saed ELShorbagy

Clinical Pathology Dept, Faculty of Medicine,

AL-Azhar University, Cairo, Egypt